Not only HR and BER are impaired (as in BRCA1-associated tumors treated by PARP inhibitors); additionally, several other important DNA damage repair pathways, which are needed to repair DNA damage induced by cisplatin, are intrinsically downregulated so that tumor cells cannot efficiently cope with the overload of DNA damage inflicted by this drug. This evidence concerns the gene BRCA1 and neoplasm.